MetaCap

Citius Oncology (CTOR) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xilio Therapeutics (XLO) has outperformed Citius Oncology (CTOR) over the past year, losing 28.3% versus a loss of 55.4%. Xilio Therapeutics is the larger company by market cap ($53.4 million vs $53.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTOR-55.44%XLO-28.29%
+50%-6%-61%
Nov 21, 20251 yearNov 20, 2026
CTOR-95.01%XLO-76.52%
+321%+103%-115%
Dec 5, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTOR versus XLO key metrics
MetricCTORXLO
Share price$0.5035$7.56
Market cap$53.25M$53.40M
1-day change-10.95%-1.11%
YTD return-49.65%-15.63%
1-year return-55.44%-28.29%
5-year return—-97.29%
P/E ratio (TTM)—11.63
EPS (TTM)$-0.48$0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$43.77M
Revenue growth (YoY)—+589.88%
Net income (latest FY)$-24.76M$-35.04M
Operating margin—-95.92%
Net margin—-80.05%
52-week high$1.83$10.71
52-week low$0.491$6.47
Distance from 52-week high-72.49%-29.41%
Analyst consensusnonenone
Avg. price target upside+694.44%+164.55%
Average volume114.02K11.54K
Shares outstanding105.76M7.06M
Employees—76
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XLO has outperformed CTOR by 27.2 percentage points over the past year.

About Citius Oncology

CTOR stock →

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

CTOR vs XLO FAQ

Which is bigger, Citius Oncology or Xilio Therapeutics?

Xilio Therapeutics (XLO) is larger, with a market capitalization of $53.40M compared with $53.25M for Citius Oncology (CTOR).

Which stock has performed better over the past year, CTOR or XLO?

XLO returned -28.29% over the past 12 months, compared with -55.44% for CTOR (price return, excluding dividends). Past performance does not predict future results.

Are Citius Oncology and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons